02:52 PM EDT, 09/04/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday it entered a partnership with the US State Department and the US President's Emergency Plan for AIDS Relief, or PEPFAR, to deliver lenacapavir for the prevention of HIV.

This collaboration aims to advance access to the injectable drug as pre-exposure prophylaxis for up to 2 million people over three years across nations supported by PEPFAR and the Global Fund, primarily low- and lower-middle-income countries, the company said.

By year-end, Gilead said it plans to complete regulatory submissions for lenacapavir in 18 countries, representing nearly 70% of the HIV burden in the region covered by its voluntary license, the company said.

Price: 112.57, Change: -0.42, Percent Change: -0.37